Patent Term Extension Application for AMTAGVI™ (lifileucel), Patent No. 11,291,687 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2024-E-3534

Patent Term Extension Application for AMTAGVI™ (lifileucel), Patent No. 11,291,687

Documents

Comments

Description

Open

Comment Period OpensAug 9, 2024

Comment Period ClosesApr 15, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; AMTAGVI FR Doc: 2026-02974	Feb 13, 2026	--

CDER

Patent Term Extension Application

Patent No. 11,291,687

AMTAGVI™ (lifileucel)

lovance Biotherapeutics, Inc. ("lovance")

Morgan, Lewis & Bockius LLP

Open